EASEE®: The Innovation in Epilepsy Treatment – The Groundbreaking Implant in the Spotlight of Medtech Outlook

Precisis GmbH is excited to announce that our innovative EASEE® Implant has been showcased as the cover story in the latest issue of Medtech Outlook, a prominent journal in the medical technology industry.
The cover story presents a comprehensive company profile, shedding light on Precisis GmbH's pioneering role in the realm of minimally invasive medical technology. Furthermore, it underscores the pivotal role of the EASEE® Implant in revolutionizing treatment approaches for pharmaco-refractory focal epilepsies. This innovative device has earned recognition as a breakthrough in medical technology, offering newfound hope and relief to patients who have previously grappled with alternative treatment options.
Read the full article here: medicaltechoutlook.com/magazines/October2023/Bioelectronics_Device

About the EASEE® System:
EASEE®, an acronym for "Epicranial Application of Stimulation Electrodes for Epilepsies," represents a cutting-edge, minimally invasive implant meticulously designed to address pharmaco-refractory focal epilepsies. Leveraging state-of-the-art bioelectronic technology, it precisely delivers stimulation to targeted brain regions, offering respite to patients unresponsive to conventional therapies. This device has garnered enthusiastic support and approval within the medical community and is commercially available in Germany, Switzerland, and Austria.

Company Profile:
Precisis GmbH, the visionary firm behind the EASEE® Implant, is deeply committed to enhancing the quality of life for individuals afflicted by severe neurological conditions. Equipped with a team of seasoned professionals, the EASEE® system has successfully obtained CE certification and market approval in Germany, Switzerland, and Austria. Precisis is also strategically planning an international expansion within the global medical technology landscape. The remarkable performance of the device underscores the immense potential for growth and innovation within the neurology and medical technology sectors. Investors aligning with Precisis GmbH not only support a technology capable of changing lives but also position themselves at the forefront of groundbreaking advancements in the industry. EASEE® is poised to make a profound impact within the medical community.